HC Wainwright Has Negative Outlook for Genelux Q1 Earnings
Research analysts at HC Wainwright lowered their Q1 2025 EPS estimates for Genelux in a report released on Monday, March 31st ...
HC Wainwright Weighs in on Defiance Silver Q3 Earnings
Equities research analysts at HC Wainwright issued their Q3 2025 EPS estimates for shares of Defiance Silver in a research ...
Fintel on MSN1d
HC Wainwright & Co. Initiates Coverage of Kairos Pharma (KAPA) with Buy Recommendation
Fintel reports that on April 3, 2025, HC Wainwright & Co. initiated coverage of Kairos Pharma (NYSEAM:KAPA) with a Buy ...
H.C. Wainwright sees increased uncertainty for Sarepta franchise
H.C. Wainwright sees increased uncertainty for Sarepta’s Elevidys franchise after the European Medicines Agency placed a clinical hold on three drug trials. The clinical hold on ...
I-Mab price target lowered to $7 from $8 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on I-Mab (IMAB) to $7 from $8 and keeps a Buy rating on the shares. The company continues to ...
Fintel on MSN2d
HC Wainwright & Co. Upgrades Sarepta Therapeutics (SRPT)
Fintel reports that on April 2, 2025, HC Wainwright & Co. upgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) ...
Kalkine Media2d
Could HC Wainwright's Appraisal Backfire on Cabaletta Bio?
Highlights,Cabaletta Bio receives a favorable evaluation from HC Wainwright.,An institutional review brings renewed focus to ...
Kalkine Media2d
Vanda Pharmaceuticals (NASDAQ:VNDA) has been given a Buy rating by HC Wainwright.
Highlights,Vanda Pharmaceuticals posts improved earnings, surpassing market expectations.,Company executives increase stock ...
Sarepta/Roche Suspend Elevidys Gene Therapy Trials In Europe After Patient Death
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shared an update on Elevidys (delandistrogene moxeparvovec-rokl), the only approved ...
Yahoo Finance3d
H.C. Wainwright Celebrates 40 Consecutive Quarters as the #1 Investment Bank in Market League Tables
NEW YORK, April 01, 2025--(BUSINESS WIRE)--H.C. Wainwright & Co., LLC ("HCW") announces a significant milestone, securing its #1 ranking for the 40th consecutive quarter in PlacementTracker’s ...
Investing8d
Nektar at H.C. Wainwright Conference: Strategic Updates on Respegg Trials
On Thursday, 27 March 2025, Nektar Therapeutics (NASDAQ: NKTR) participated in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference. The company provided a strategic ...